1887

Abstract

Residual viraemia is detectable in the majority of human immunodeficiency virus (HIV)-infected subjects with plasma HIV-1 RNA <50 copies ml. In the present study, the impact of repeated treatment interruptions on residual HIV-1 viraemia was investigated in 58 subjects enrolled in the ISS-PART, a multicentre, randomized clinical trial comparing 24 months of continuous (arm A) and intermittent (arm B) highly active antiretroviral therapy (HAART). Residual viraemia was measured by a modified Roche Amplicor HIV-1 RNA assay (limit of detection 2.5 copies ml). At baseline, the median value of residual viraemia was 2.5 copies ml in both arms; after 24 months, the median value was 2.5 in arm A and 8.3 in arm B. The median change from baseline to month 24 was significantly different between patients under continuous or intermittent HAART: 0 copies ml (range −125.2 to +82.7) of HIV-1 RNA in arm A versus 2.1 copies ml (range −80 to +46.8) in arm B (=0.024). These results suggest that intermittent HAART tends to modify HIV-1 viraemia set point even if a virological response is achieved after HAART reinstitution.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.004630-0
2009-01-01
2020-07-07
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/1/121.html?itemId=/content/journal/jmm/10.1099/jmm.0.004630-0&mimeType=html&fmt=ahah

References

  1. Ananworanich J., Hirschel B. 2007; Intermittent therapy for the treatment of chronic HIV infection. AIDS 21:123–124 [CrossRef]
    [Google Scholar]
  2. Dornadula G., Zhang H., VanUitert B., Stern J., Livornese L. Jr, Ingerman L. J., Witek J., Kedanis R. J., Natkin J. other authors 1999; Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282:1627–1632 [CrossRef]
    [Google Scholar]
  3. Finzi D., Blanckson J., Siliciano J. D., Margolick J. B., Chadwick K., Pierson T., Smith K., Liszewicz J., Lori F. other authors 1999; Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512–517 [CrossRef]
    [Google Scholar]
  4. Frost S. D. W., Martinez-Picado J., Ruiz L., Clotet B., Brown A. J. 2002; Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection. J Virol 76:968–979 [CrossRef]
    [Google Scholar]
  5. Havlir D. V., Strain M. C., Clerici M., Ignacio C., Trabattoni D., Ferrante P., Wong J. K. 2003; Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type-1 infected persons treated with suppressive antiretroviral therapy for five years. J Virol 77:11212–11219 [CrossRef]
    [Google Scholar]
  6. Havlir D. V., Koelsch K. K., Strain M. C., Margot N., Biao L., Ignacio C. C., Miller M. D., Wong J. K. 2005; Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 191:1164–1168 [CrossRef]
    [Google Scholar]
  7. Maldarelli F., Palmer S., King M. S., Wiegand A., Polis M. A., Mican J., Kovacs J. A., Davey R. T., Rock-Kress D. other authors 2007; ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3:e46 [CrossRef]
    [Google Scholar]
  8. McKinnon J. E., Arribas J. R., Pulido F., Delgado R., Mellors J. W. 2006; The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS 20:2331–2335 [CrossRef]
    [Google Scholar]
  9. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G. J., Brun S. C., Kempf D. J., Mellors J. W., Coffin J. M., King M. S. 2008; Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105:3879–3884 [CrossRef]
    [Google Scholar]
  10. Palmisano L., Giuliano M., Nicastri E., Pirillo M. F., Andreotti M., Galluzzo C. M., Bucciardini R., Fragola V., Andreoni M., Vella S. 2005; Residual viremia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 19:1843–1847 [CrossRef]
    [Google Scholar]
  11. Palmisano L., Giuliano M., Bucciardini R., Fragola V., Andreotti M., Galluzzo C. M., Pirillo M. F., Weimer L. E., Arcieri R. other authors 2007; Determinants of virologic and immunologic outcomes in chronically HIV-infected subjects undergoing repeated treatment interruptions: the Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study. J Acquir Immune Defic Syndr 46:39–47
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.004630-0
Loading
/content/journal/jmm/10.1099/jmm.0.004630-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error